Inflammatory Response Inhibition and Improvement of COVID-19 Symptoms in COVID-19 Patients by Combination of Antiviral Regimen and Tanreqing Injection

The present study explored the inflammatory response and clinical efficacy of Tanreqing injection in combination with antiviral therapy in patients with coronavirus disease (COVID-19). The results demonstrated that the levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in the treatment group were significantly lower than those in the control group (p < 0.05). Clinical efficacy assessment revealed a significant improvement in the time necessary for image absorption improvement in the treatment group (p < 0.05), while the time taken for fever and muscle soreness symptoms to resolve significantly reduced (p < 0.05). Furthermore, the time taken to obtain a negative COVID-19 test result was significantly shortened (p < 0.05). Tanreqing injection combined with antiviral treatment improved clinical symptoms of COVID-19 faster than when the anti-viral treatments were used alone and this may be related to the reduction in inflammatory response.